BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US

BioMarin Pharmaceutical has offices in San Rafael, Novato, Kronberg im Taunus, Cork and in 29 other locations

San Rafael, US (HQ)

770 Lindaro St

Hong Kong, HK

Mass Mutual Tower 38 Gloucester Rd

Mocoa, CO

96 Cra. 9

London, GB

10 Bloomsbury Way

Leiden, NL

Biopartner Gebouw 1 21 J.H. Oortweg

Dublin, IE

Saint James House Adelaide Rd

BioMarin Pharmaceutical's revenue was reported to be $303.7 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 303.7 m |

## Gross profit (Q1, 2017) | 253.7 m |

## Gross profit margin (Q1, 2017), % | 84% |

## Net income (Q1, 2017) | (16.3 m) |

## EBIT (Q1, 2017) | (20.2 m) |

## Market capitalization (21-Jul-2017) | 15.2 b |

## Cash (31-Mar-2017) | 348.2 m |

BioMarin Pharmaceutical's current market capitalization is $15.2 b.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 548.5 m | 751 m | 889.9 m | 1.1 b |

## Revenue growth, % | 37% | 18% | 26% | |

## Cost of goods sold | 95.7 m | 129.8 m | 152 m | 209.6 m |

## Gross profit | 452.7 m | 621.3 m | 737.9 m | 907.2 m |

## Gross profit Margin, % | 83% | 83% | 83% | 81% |

## R&D expense | 661.9 b | |||

## General and administrative expense | 476.6 b | |||

## Operating expense total | 608.8 m | 843.9 m | 1 b | 1.9 b |

## EBIT | (156 m) | (92.9 m) | (110.7 m) | (803.4 m) |

## EBIT margin, % | (28%) | (12%) | (12%) | (72%) |

## Interest expense | 10.4 m | 36.6 m | 38.2 m | 39.5 m |

## Interest income | 3.1 m | 5.9 m | 4.5 m | 7.5 b |

## Pre tax profit | (176.5 m) | (124.9 m) | (154.7 m) | (831.1 m) |

## Income tax expense | (150 k) | 9.1 m | 17.1 m | (200.8 m) |

## Net Income | (176.4 m) | (134 m) | (171.8 m) | (630.2 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 191.8 m | 176.8 m | 203.3 m | 250.5 m | 208.9 m | 236.7 m | 300 b | 279.9 m | 303.7 m |

## Cost of goods sold | 31.2 m | 29.9 m | 32.8 m | 39.9 m | 36.7 m | 43.1 m | 51.6 b | 50.7 m | 50 m |

## Gross profit | 160.6 m | 146.9 m | 170.5 m | 210.6 m | 172.2 m | 193.6 m | 248.4 b | 229.2 m | 253.7 m |

## Gross profit Margin, % | 84% | 83% | 84% | 84% | 82% | 82% | 83% | 82% | 84% |

## R&D expense | 107.7 m | 125.7 m | 142.1 m | 157.9 m | 158.7 m | 158.8 m | 167 b | 160.8 m | 145 m |

## General and administrative expense | 68.1 m | 74.6 m | 92.8 m | 101.5 m | 94 m | 105.3 m | 110 b | 118.8 m | 120 m |

## Operating expense total | 175.8 m | 200.3 m | 234.9 m | 259.4 m | 252.8 m | 264.1 m | 277 b | 279.6 m | 265 m |

## EBIT | (18.9 m) | 11.2 m | (65.9 m) | (64.2 m) | (81.9 m) | (80.9 m) | (573 b) | (60.1 m) | (20.2 m) |

## EBIT margin, % | (10%) | 6% | (32%) | (26%) | (39%) | (34%) | (191%) | (21%) | (7%) |

## Interest expense | (9.2 m) | (9.1 m) | (9.5 m) | (10 m) | (9.4 m) | (9.8 m) | (9.9 b) | (10 m) | (10.1 m) |

## Interest income | 1.7 m | 1.4 m | 683 k | 1 m | 1.3 m | 1.6 m | 1.4 b | 1.6 m | 3.1 m |

## Pre tax profit | (27.7 m) | 3.2 m | (74.7 m) | (82.5 m) | (90.4 m) | (89.1 m) | (583 b) | (66.8 m) | (24.3 m) |

## Income tax expense | 5.8 m | (4.2 m) | (7.2 m) | (555 k) | 483 k | (24 m) | |||

## Net Income | (33.5 m) | 7.4 m | (67.5 m) | (82 m) | (90.9 m) | (85.1 m) | (424 b) | (42.8 m) | (16.3 m) |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 568.8 m | 875.5 m | 397 m | 408.3 m |

## Accounts Receivable | 117.8 m | 144.5 m | 165 m | 215.3 m |

## Inventories | 162.6 m | 199.5 m | 271.7 m | 355.1 m |

## Current Assets | 1.1 b | 1.4 b | 1.1 b | 1.4 b |

## PP&E | 319.3 m | 523.5 m | 704.2 m | 798.8 m |

## Goodwill | 54.3 m | 54.3 m | 197 m | 197 m |

## Total Assets | 2.2 b | 2.5 b | 3.7 b | 4 b |

## Accounts Payable | 370.5 m | |||

## Current Liabilities | 183.3 m | 235.7 m | 445.5 m | 439.3 m |

## Total Liabilities | 1.3 b | |||

## Additional Paid-in Capital | 2.1 b | 2.4 b | 3.4 b | 4.3 b |

## Retained Earnings | (715.8 m) | (849.8 m) | (1 b) | (1.5 b) |

## Total Equity | 1.3 b | 1.5 b | 2.4 b | 2.8 b |

## Financial Leverage | 1.7 x | 1.6 x | 1.6 x | 1.5 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 584.7 m | 398 m | 900.6 m | 440.7 m | 376.3 m | 270.5 m | 306 m | 707.3 m | 348.2 m |

## Accounts Receivable | 122.3 m | 121.4 m | 175.7 m | 186.1 m | 148.9 m | 180.8 m | 214.2 m | 215.9 m | 230.3 m |

## Inventories | 193.5 m | 204.4 m | 222.8 m | 237.5 m | 262.1 m | 297 m | 326.6 m | 347.4 m | 384.1 m |

## Current Assets | 1.2 b | 1.1 b | 1.5 b | 1.2 b | 1.2 b | 992.8 m | 1.1 b | 1.7 b | 1.4 b |

## PP&E | 469.9 m | 486.7 m | 538.1 m | 568.1 m | 604.5 m | 716.9 m | 724.5 m | 729.8 m | 824 m |

## Goodwill | 54.3 m | 54.3 m | 202.4 m | 202.4 m | 202.4 m | 197 m | 197 m | 197 m | 197 m |

## Total Assets | 2.3 b | 2.4 b | 3.7 b | 3.6 b | 3.6 b | 3.7 b | 3.1 b | 3.8 b | 3.9 b |

## Accounts Payable | 166.7 m | 206.6 m | 230.2 m | 256.3 m | 296.2 m | 290.6 m | 292.3 m | 306.1 m | 272.4 m |

## Current Liabilities | 166.7 m | 206.6 m | 305.5 m | 347.7 m | 390.5 m | 388 m | 364.6 m | 377.3 m | 340.2 m |

## Additional Paid-in Capital | 2.2 b | 2.3 b | 3.3 b | 3.3 b | 3.4 b | 3.4 b | 3.5 b | 4.2 b | 4.3 b |

## Retained Earnings | (787.4 m) | (780 m) | (917.3 m) | (999.3 m) | (1.1 b) | (1.1 b) | (1.5 b) | (1.6 b) | (1.5 b) |

## Total Equity | 1.5 b | 1.5 b | 2.4 b | 2.3 b | 2.3 b | 1.9 b | 2.6 b | 2.8 b | |

## Financial Leverage | 1.6 x | 1.6 x | 1.5 x | 1.6 x | 1.6 x | 1.6 x | 1.5 x | 1.4 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (176.4 m) | (134 m) | (171.8 m) | (630.2 m) |

## Depreciation and Amortization | 47.3 m | 56.7 m | 47.2 m | 96.9 m |

## Accounts Receivable | (8.8 m) | (27 m) | (16 m) | (51.5 m) |

## Inventories | (34 m) | (37 m) | (51 m) | (64.5 m) |

## Cash From Operating Activities | (59.6 m) | (73.5 m) | (221.7 m) | (227.8 m) |

## Purchases of PP&E | (65.1 m) | (118.8 m) | (227.7 m) | (148.4 m) |

## Cash From Investing Activities | (298.8 m) | 194.6 m | (1.2 b) | (484 m) |

## Cash From Financing Activities | 746.7 m | 185.7 m | 927.9 m | 727.1 m |

## Income Taxes Paid | 14.9 m | 35 m | 16.1 m | 95.9 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (33.5 m) | 7.4 m | (67.5 m) | (82 m) | (90.9 m) | (85.1 m) | (424 b) | (42.8 m) | (16.3 m) |

## Accounts Receivable | 122.3 m | 121.4 m | 175.7 m | 186.1 m | 148.9 m | 180.8 m | 214.2 m | 215.9 m | 230.3 m |

## Inventories | 193.5 m | 204.4 m | 222.8 m | 237.5 m | 262.1 m | 297 m | 326.6 m | 347.4 m | 384.1 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 132.5 k |

## Financial Leverage | 1.4 x |

BioMarin Pharmaceutical's Patent Applications was reported to be 426 in FY, 2016

- Source: SEC Filings

Source: 52 public H-1B filings from BioMarin Pharmaceutical